Additionally, our investigation revealed the preferential expression of CYP3A5 in cancer cells expressing the GSC markers SOX2 and CD133 via co-immunofluorescence (co-IF) staining of human GBM surgical specimens (Fig. 2I). This evidence concerns the gene PROM1 and glioblastoma.